Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

Medicine, Oncology, Pharmacology +13

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · Zurich Open Repository and Archive (University of Zurich) · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

Hidetoshi Sumimoto, Fumie Imabayashi, Tomoko Iwata et al. · The Journal of Experimental Medicine · 2006 · 713 citations · Full text

Life Sciences, Immunology, Oncology +17

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13